

Veracyte, Inc. Investor Relations Department 6000 Shoreline Court Suite 300 South San Francisco, CA 94080 United States

Visit IR website \square^2 Sign-up for Email alerts \square^2

NASDAQ: VCYT	
Last Trade:	8.52
Trade Time:	4:00 PM ET Sep 20, 2017
Change:	0.48 🕈 (+5.970%)
Day Range	8.04 - 8.55
52-Week Range	5.82 - 9.71
Volume	213,441

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. (more)

Stock Performance



Press Releases [View all]

Sep 19, 2017

Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together

Sep 19, 2017

<u>Veracyte Launches Campaign to Save Lives</u> through Early Screening for Lung Cancer

Sep 13, 2017

<u>Veracyte to Present at the Cantor Fitzgerald</u> <u>Global Healthcare Conference</u>

Aug 24, 2017

<u>Veracyte to Present at the Morgan Stanley</u> 15th Annual Global Healthcare Conference

Jul 31, 2017

<u>Veracyte Announces Second Quarter 2017</u> Financial Results

Upcoming Events [View all]

Sep 26, 2017 2:15 PM ET

Cantor Fitzgerald Global Healthcare Conference

Financials [View all]

First Quarter Financial Results

Mar 1, 2017

Annual Report (10-K)

Apr 21, 2017

Proxy Statement (DEF 14A)

Jul 31, 2017

Quarterly Report (10-Q)

May 3, 2017

Quarterly Report (10-Q)

Nov 3, 2016

Quarterly Report (10-Q)